Streetbeat News

Products Services

CHPT

ChargePoint and LG Electronics have announced a strategic partnership to develop innovative EV charging solutions. LG's hardware will be integrated with ChargePoint's software, aiming to enhance the EV charging experience.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 12:12 pm

DMRC

Digimarc has announced a partnership with OMRON to enhance industrial automation solutions. This collaboration aims to integrate Digimarc's digital watermarking technology with OMRON's automation systems to improve efficiency and accuracy in manufacturing processes.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 12:11 pm

TSLA

TSLL

TSLS

Tesla, Inc. (NASDAQ:TSLA) has been in the spotlight with recent news, including the approval of Elon Musk's $56 billion pay package and the development of new vehicles. Despite positive developments, challenges such as slowing EV sales and economic headwinds persist. Direxion's leveraged ETFs, TSLL and TSLS, offer traders opportunities to bet on TSLA's short-term movements.

Portfolio Pulse from Joshenomoto@benzinga.com

June 18, 2024 | 12:06 pm

TAK

Takeda announced favorable long-term data from its Phase 3 ADVANCE-CIDP 3 clinical trial of HYQVIA in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The results support HYQVIA as an effective long-term treatment option for maintaining stable disease course in CIDP. These findings will be presented at the PNS Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 12:06 pm

ASMB

Assembly Biosciences has dosed the first participant in its Phase 1b trial of ABI-4334, a next-generation capsid assembly modulator for the treatment of chronic Hepatitis B.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 12:06 pm

MRK

PFE

The FDA has approved Merck's Capvaxive, the first pneumococcal conjugate vaccine designed for adults, covering 21 strains of bacteria. This approval is significant as it offers broader protection compared to Pfizer's Prevnar 20. Additionally, the FDA approved Merck's Keytruda for a new endometrial carcinoma indication.

Portfolio Pulse from Vandana Singh

June 18, 2024 | 12:05 pm

ERAS

Erasca, Inc. (NASDAQ:ERAS) has initiated the SEACRAFT-2 Phase 3 trial to evaluate the combination of naporafenib and trametinib in patients with NRAS-mutant melanoma. Naporafenib, a pan-RAF inhibitor, has shown favorable results in earlier trials and is being developed for multiple RAS/MAPK pathway-driven tumors. The trial's first stage results are expected in 2025.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 12:05 pm

AEMD

Aethlon Medical has received full ethics approval to conduct a clinical trial for its Hemopurifier in cancer patients with solid tumors unresponsive to anti-PD-1 therapy. This approval marks a significant milestone for the company in advancing its medical technology.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 12:05 pm

AUID

AuthID has expanded its biometric identity platform by integrating Syntrove's risk and fraud technology. This OEM agreement aims to enhance fraud prevention across various sectors including banking, insurance, gaming, crypto, and supply-chain enterprises.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 12:04 pm

LGND

The FDA has approved CAPVAXIVE, the sixth product utilizing Pfenex Expression Technology. Ligand Pharmaceuticals (LGND) is entitled to royalties on global sales.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 12:03 pm